Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.
about
The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytesUse of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpointThe triple combination indinavir-zidovudine-lamivudine is highly synergistic.Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalationPharmacodynamics of abacavir in an in vitro hollow-fiber model system.Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.HIV resistance to antiretroviral drugs: mechanisms, genotypic and phenotypic resistance testing in clinical practice.Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.Novel clinical trial designs for the development of new antiretroviral agentsVariability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practiceUpdated clinical pharmacologic considerations for HIV-1 protease inhibitors.In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hoursOlder HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction.Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance.A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184VSusceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors.Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir.Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation.Clinical Pharmacologic Considerations for HIV-1 Protease Inhibitors.Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.Treatment comparisons for a partially categorical outcome applied to a biomarker with assay limit.Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.Carbamazepine--indinavir interaction causes antiretroviral therapy failure.Genetic evolution of HIV in patients remaining on a stable HAART regimen despite insufficient viral suppression
P2860
Q28486204-5351F793-93C8-4BE2-A118-273C4C7D57D3Q30620954-CB590939-5BB8-42EF-9F38-FEBA0A25A425Q33979237-24437733-EEDD-4053-BCC2-83311397431EQ33980106-FA7CD246-3747-41EC-ACC1-740A25EDAD96Q34105353-84E29EC6-D113-4760-897F-4067A2BA9826Q34307105-6226EC76-A492-4387-A34E-82317E57C884Q35014914-40123146-8ECD-4AA3-B1EC-57F6CE2CEAF8Q35827870-4EB75DBC-9873-48B9-9323-BACBC894ABA0Q35931303-7383AA23-2506-4A3A-80DA-5CC03FEA59D7Q36024483-EFD7DB02-2305-4674-A6CE-2ABB75F13C3EQ36223724-4EEF5747-C96F-405D-B725-43BC7930F2C2Q36880866-7679D1C0-49E1-40EC-9B16-CDEC8954C6B3Q37247131-BA028098-F50A-41EE-9FC4-AEE624101342Q39459306-910519F2-9DFB-40AF-93CE-9FA07A6FD44AQ39473036-7882358A-31DE-40EA-ABE9-DB06A5949020Q39473811-0EB25BBC-CCAD-47EE-BF0D-39A32E901B42Q39474146-245DA33A-1778-49E3-A14D-53CD305A5A60Q39653093-D087287D-97E5-42C9-9E25-A15543353245Q40695402-5AEC300A-749B-49DE-A834-55CCA7925F03Q41269323-38258D29-D8FB-4923-A4CA-E94611549F8BQ43843561-29A2C36E-36CA-480A-B45F-C6F726F65D0CQ48325069-DD78DB3D-F718-4C6F-81A8-ACCAE267D83DQ54054782-D024E813-A7D4-457D-A3E9-649F14E4910AQ57877709-79DBD8D1-096E-48E9-929E-774E52C96BC8
P2860
Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
Factors influencing the emerge ...... , and pharmacologic variables.
@en
Factors influencing the emerge ...... , and pharmacologic variables.
@nl
type
label
Factors influencing the emerge ...... , and pharmacologic variables.
@en
Factors influencing the emerge ...... , and pharmacologic variables.
@nl
prefLabel
Factors influencing the emerge ...... , and pharmacologic variables.
@en
Factors influencing the emerge ...... , and pharmacologic variables.
@nl
P2093
P356
P1476
Factors influencing the emerge ...... , and pharmacologic variables.
@en
P2093
Bilello JA
Chodakewitz J
Drusano GL
P304
P356
10.1086/515631
P407
P577
1998-08-01T00:00:00Z